Tumour Mutational Burden is a promising biomarker to predict response to immunotherapy. In this thesis, statistical methods of supervised learning were used to predict TMB: GLM, Decision Trees and SVM. Predictions were based on data from targeted DNA sequencing, using variants found in the exonic, intronic, UTR and intergenic regions of the human DNA. This project was of an exploratory nature, performed in a pan-cancer setting. Both regression and classification were considered. The purpose was to investigate whether variants found in these regions of the DNA sequence are useful when predicting TMB. Poisson regression and Negative binomial regression were used within the framework of GLM. The results indicated deficiencies in the model assumptions and that the use of GLM for the application is questionable. The single regression tree did not yield satisfactory prediction accuracy. However, performance was improved by using variance reducing methods such as bagging and random forests. The use of boosted regression trees did not yield any significant improvement in prediction accuracy. In the classification setting, binary as well as multiple classes were considered. The distinction between classes was based on commonly used thresholds in clinical care to achieve immunotherapy. SVM and classification trees yielded high prediction accuracy for the binary case: a misclassification rate of 0.0242 and 0 respectively for the independent test set. In the multiple classification setting, bagging and random forests were implemented, yet, did not improve performance over the single classification tree. SVM produced a misclassification rate of 0.103, and the corresponding number for the single classification tree was 0.109. It was concluded that SVM and Decision trees are suitable methods for predicting TMB based on targeted gene panels. However, to obtain reliable predictions, there is a need to move from a pan-cancer setting to a diagnosis-based setting. Furthermore, parameters affecting TMB, like pre-analytical factors need to be included in the statistical analysis. / Denna uppsats undersöker tre metoder inom statistisk inlärning: GLM, Decision Trees och SVM, med avsikt att förutsäga mutationsbörda, TMB, för cancerpatienter. Metoderna har applicerats både inom regression och klassificering. Förutsägelser gjordes baserat på data från panel-baserad DNA-sekvensering som innehåller varianter från kodande, introniska UTR och intergeniska regioner av mänskligt DNA. Projektet ämnar att undersöka om varianter från dessa regioner av DNA-sekvensen kan vara användbara för att förutsäga mutationsbördan för en patient. Poisson-regression och Negativ Binomial-regression undersöktes inom GLM. Resultaten indikerade på brister i modellerna och att GLM inte är lämplig för denna tillämpning. Regressionsträden gav inte tillräckligt noggranna förutsägelser, men implementering av bagging och random forests förbättrade modellernas prestanda. Boosting förbättrade inte resultaten. Inom klassificering användes både binära klasser och multipla klasser. Avgränsningen mellan klasser baserades på kända gränser för TMB inom vården för att få immunoterapi. SVM och decision trees gav god prestanda för binär klassificering, med ett klassificeringsfel på 0.024 för SVM och 0 för decision trees. Bagging och random forests implementerades för det multipla fallet inom decision trees, men förbättrade inte prestandan. För multipla klasser gav SVM ett klassificeringnsfel på 0.103 och decision trees 0.109. Både SVM och decision trees visade sig vara lämpliga metoder för för att förutse värdet på TMB. Däremot, för att förutsägelserna ska vara tillförlitliga finns det ett behov av att göra denna typ av analys för varje enskild cancerdiagnos. Dessutom finns det ett behov av att inkludera parametrar från den bioinformatiska processen i den statistiska analysen.

<p>Sea cucumbers have been found to contain bioactive compounds such as saponin, fucoidan, frondoside, and glycosides that have pharmacological properties like antitumor, antibacterial, anti-inflammation, and antihyperglycemic activity. Although several species of sea cucumbers have been studied and reared for the food and medicinal industries, not much research has been conducted on the species in the waters of the Eastern United States. In this research, physiological and immunological parameters of coelomic fluid from <em>Cucumaria</em> <em>frondosa</em>, <em>Isostychopus</em> <em>badionotus</em>, and <em>Pentacta</em> <em>pygmaea</em> were compared to find the most promising candidate with these properties and pharmacological benefits. We found that <em>C. frondosa</em> was the species with the best immunological and physiological parameters among the three studied. <em>C. frondosa</em> illustrated that its coelomic fluid contains the highest concentrations of cells and lysozymes that had the highest activity. Using <em>C. frondosa</em>’s tissue extracts and coelomic fluid, the ability of the extracts and coelomic fluid to inhibit murine melanoma cells (B16-F10) and modulate T-lymphocytes <em>in vitro</em> were investigated. Although no significant differences were seen statistically, the experiments illustrated that T-lymphocytes were highly activated at higher concentrations (0.001g/uL-0.0002g/uL) for tissue extracts and at lower concentrations (0.000008g/uL) for coelomic fluid. On the other hand, melanoma cells were inhibited highest at lower concentrations (0.000008g/uL-0.0000016/uL). In addition to these studies, the antibacterial activity of <em>C. frondosa</em> extract was tested on ten pathogenic bacterial species. Antibacterial activity of the <em>C. frondosa</em> extract was not seen in this experiment. However, hemolytic activity by compounds present in <em>C. frondosa</em> extracts was seen in blood agars culturing <em>Streptococcus pneumoniae</em> and <em>Enterococcus faecalis</em> in our experiment. Lastly, an <em>in vivo </em>study was conducted to see if <em>C. frondosa</em> extract can modulate stress in Nile tilapia. In our experiment, we observed that <em>C. frondosa</em> extract was able to enhance the activity of one of the parameters, phagocytic capacity significantly. However, we are not able to conclude that <em>C. frondosa</em> extract was able to mitigate chronic stress from the results obtained. Overall, observing the results from the projects, we cannot conclude that <em>C. frondosa</em> extracts illustrated pharmacological properties. Extensive studies are recommended and required to use <em>C. frondosa</em> extract for medicinal purposes. </p>

Radiomics analyses commonly apply imaging features of different complexity for the prediction of the endpoint of interest. However, the prognostic value of each feature class is generally unclear. Furthermore, many radiomics models lack independent external validation that is decisive for their clinical application. Therefore, in this manuscript we present two complementary studies. In our modelling study, we developed and validated different radiomics signatures for outcome prediction after neoadjuvant chemoradiotherapy (nCRT) in patients with locally advanced rectal cancer (LARC) based on computed tomography (CT) and T2-weighted (T2w) magnetic resonance (MR) imaging datasets of 4 independent institutions (training: 122, validation 68 patients). We compared different feature classes extracted from the gross tumour volume for the prognosis of tumour response and freedom from distant metastases (FFDM): morphological and first order (MFO) features, second order texture (SOT) features, and Laplacian of Gaussian (LoG) transformed intensity features. Analyses were performed for CT and MRI separately and combined. Model performance was assessed by the area under the curve (AUC) and the concordance index (CI) for tumour response and FFDM, respectively. Overall, intensity features of LoG transformed CT and MR imaging combined with clinical T stage (cT) showed the best performance for tumour response prediction, while SOT features showed good performance for FFDM in independent validation (AUC = 0.70, CI = 0.69). In our external validation study, we aimed to validate previously published radiomics signatures on our multicentre cohort. We identified relevant publications on comparable patient datasets through a literature search and applied the reported radiomics models to our dataset. Only one of the identified studies could be validated, indicating an overall lack of reproducibility and the need of further standardization of radiomics before clinical application.

Yes / CC-1065, the duocarmycins and yatakemycin are members of a family of ultrapotent antitumour antibiotics that have been the subject of extensive investigations due to their mode of action and potential in the design of new anticancer therapeutics. The natural products and their analogues exert their effects through a sequence selective alkylation of duplex DNA in the minor groove at the N3 of adenine. An understanding of their structure and its effect on biological activity has been derived through chemical synthesis and has also generated new potential lead compounds. These studies form the first section of the review. The desire to progress these compounds to clinic has also led to studies of bioconjugation and prodrug formation and this is discussed in the second section of the review. The combination of synthesis with key biological experiments is a powerful tool to define the requirements for the development of natural products as potential therapeutic agents. The studies described herein form an excellent paradigm for the study and development of other natural products. / EPSRC, Yorkshire Cancer Research, Big C Cancer Research, UCB Pharma

To prevent further brain tumour growth, malignant tissue should be removed as completely as possible in neurosurgical operations. Therefore, differentiation between tumour and brain tissue as well as detecting functional areas is very important. Hyperspectral imaging (HSI) can be used to get spatial information about brain tissue types and characteristics in a quasi-continuous reflection spectrum. In this paper, workflow and some aspects of an adapted hardware system for intraoperative hyperspectral data acquisition in neurosurgery are discussed. By comparing an intraoperative with a laboratory setup, the influences of the surgical microscope are made visible through the differences in illumination and a pixel- and wavelength-specific signal-to-noise ratio (SNR) calculation. Due to the significant differences in shape and wavelength-dependent intensity of light sources, it can be shown which kind of illumination is most suitable for the setups. Spectra between 550 and 1,000 nm are characterized of at least 40 dB SNR in laboratory and 25 dB in intraoperative setup in an area of the image relevant for evaluation. A first validation of the intraoperative hyperspectral imaging hardware setup shows that all system parts and intraoperatively recorded data can be evaluated. Exemplarily, a classification map was generated that allows visualization of measured properties of raw data. The results reveal that it is possible and beneficial to use HSI for wavelength-related intraoperative data acquisition in neurosurgery. There are still technical facts to optimize for raw data detection prior to adapting image processing algorithms to specify tissue quality and function.:Abstract Introduction Materials and methods (Clinical workflow and setup for hyperspectral imaging process, Characteristics of the lighting, Characteristics of the hyperspectral imaging camera, Spectral data acquisition and raw data pre-processing in neurosurgery, Spectral data evaluation) Results (Spectral characteristics of the lighting, SNR of the HSI camera, Data acquisition and raw data preprocessing during neurosurgical operation, Spectral data evaluation) Discussion Conclusions

Vasoaktives Intestinales Peptid (VIP) ist ein 28meres Neuropeptid, das eine Vielzahl biologischer Aktivitäten ausübt, welche durch die Bindung an die heptahelikalen Transmembranrezeptoren VPAC1 und VPAC2 vermittelt werden. VPAC1 ist auf der Oberfläche vieler Tumorzellen überexprimiert. Daher ist VIP gekoppelt mit Signalmolekülen wie z.B. Fluoreszenzfarbstoffen eine interessante Zielstruktur für die optische Detektion von Tumoren. Der Einsatz von VIP in der Tumordiagnostik ist jedoch aufgrund der schnellen proteolytischen Degradation stark limitiert. In der vorliegenden Arbeit wurden VIP-Analoga mit höherer in vitro und in vivo Stabilität identifiziert und synthetisiert. Hierfür wurde eine neue Synthesestrategie entwickelt, welche die hochparallele Herstellung von löslichen VIP-Farbstoff-Konjugaten auf Cellulosemembranen (Spotsynthese) erlaubt. Es wurden 533 N-terminal Carbocyanin-farbstoff-markierte VIP-Analoga synthetisiert, wobei jeder VIP-Rest durch alle übrigen 19 L-Aminosäuren ausgetauscht wurde (Substitutionsanalyse). Alle Analoga wurden mittels Durchflußzytometrie hinsichtlich ihrer Bindung/Internalisierung an VPAC1-überexprimieren-den Zellen getestet. Diese Ergebnisse führten zur Identifizierung von VIP Aminosäureresten, die für die Wechselwirkung mit VPAC1 essentiell sind und lieferten weiterhin Hinweise über eine vorwiegend helikale Struktur des Rezeptor-gebundenen VIPs. Durch Einbau des Farbstoffs an alle VIP-Reste wurden die für die Wechselwirkung mit VPAC1 günstigen Positionen ermittelt. In Kompetitionstudien und cAMP-Assays ausgewählter Farbstoff-markierter VIP-Konjugate wurde demonstriert, daß sowohl die Spezifität als auch die Produktion von cAMP mit Hilfe der Modifikation der Farbstoffposition gesteigert werden konnte. Für die in Rattenleber getestete metabolische Stabilität der VIP-Analoga zeigte die Farbstoffposition nur einen geringen Einfluß. Die metabolische Stabilität konnte jedoch durch eine einzige Modifikation an Position 8 (Asp8 ® Arg8) erhöht werden. Weiterhin wurde das [Arg8]-VIP-Analogon als Kontrastmittel in in vivo Imaging-Experimenten mit VPAC1-überexprimierenden Tumoren inokulierter Mäuse appliziert. Hierbei wurden die Ergebnisse der Stabilitätstests in Rattenleber bestätigt. Das N-terminal farbstoffmarkierte [Arg8]-VIP-Derivat zeigte gegenüber dem nativen N-terminal markierten VIP-Konjugat eine höhere Halbwertszeit in vivo. Darüber hinaus konnte mit [Arg8]-VIP ein höherer Fluoreszenzkontrast zwischen normalen und Tumorgewebe induziert werden. / Vasoactive Intestinal Peptide (VIP) is a 28meric neuropeptide with a broad range of biological activities which are mediated via binding to the heptahelical transmembrane receptors VPAC1 and VPAC2. Since VPAC1 is overexpressed on the surface of numerous tumour cells, VIP coupled with signal structures like fluorescence dyes is an interesting target for the tumour detection in the near-infrared range. The use of VIP in tumour diagnosis is limited due to the rapid proteolytic degradation and therefore suggests need for optimised VIP-analogues with enhanced stability. In the present work a complete substitutional analysis of VIP N-terminally labelled with carbocyanine dyes was performed. For that reason a new synthetic strategy has been developed, which allows the parallel production of soluble VIP-dye conjugates using the spot synthesis technique. The resulting 560 derivatives were tested for binding and internalisation using VPAC1-overexpressing cells by means of flow cytometry. Based on these results a VIP binding motif has been delineated, which facilitates the modification of VIP concerning stability enhancement and preservation of binding characteristics. Using a dye-walk the dye-coupling positions beneficial for cell binding were identified. Radioactive competitions studies and cAMP assays of selected dye-labeled VIP-conjugates demonstrated that specifity as well as production of cAMP or biological activity has been increased by alteration of the dye-position. For increasing metabolic stability of labelled VIP-analogues the dye-position showed little influence. But is has been shown that stability of VIP was increased by only one modification at position 8 (Asp8®Arg8). Furthermore [Arg8]-VIP-derivative has been used as a contrasting agent in in vivo-Imaging experiments with VPAC1-overexpressing tumours inoculated in mice. Here the results of stability test in rat liver extract were confirmed. N-terminally dye-labelled [Arg8]-VIP analogue revealed higher half-life-time in vivo towards N-terminally labelled native VIP-derivative. In addition the [Arg8]-VIP induced a higher tumour contrast between normal and tumour tissue.

Der adoptive Transfer von T-Zell-Rezeptor (TZR) modifizierten T-Zellen gegen krebsspezifische Antigene ist ein vielversprechender Ansatz in der Immuntherapie. Geeignete Zielmoleküle für diese Therapie sollten wichtig für das Überleben von Krebszellen sein und zudem in ausreichenden Mengen auf der Zelloberfläche exprimiert werden, um von T-Zellen erkannt zu werden. Die Identifizierung dieser Zielmoleküle ist jedoch eine Herausforderung und erfordert eine intensive Charakterisierung, um eine ausreichende Prozessierung und Präsentation auf den Tumorzellen zu validieren. Ziel dieser Arbeit war, HLA-A2-spezifische Neoepitope als Zielmoleküle für adoptive T-Zell-Therapie zu validieren. Dafür wurden erfolgreich Immunantworten in einem humanen transgenen Mausmodell nach Peptidimmunisierung induziert und TZRs mit hoher Affinität isoliert. Trotz einer hohen funktionellen Avidität von H3.3K27M-spezifischen T-Zellen wurde keine Erkennung von Tumorzellen erreicht. Zweitens wurden TZR-transduzierte T-Zellen gegen die häufige Melanommutation Rac1P29S isoliert, welche zytotoxisch gegen Melanomzelllinien waren. Letztlich wurde beobachtetet, dass TZRs mit hoher Affinität gegen gespleißte Kras und Rac2 Epitope, welche durch Proteasom-katalysiertes Peptidspleißen erzeugt wurden, keine Immunantwort gegen endogen exprimierte Mutationen hervorrufen konnten. Daraus lässt sich schließen, dass gespleißte Epitope wahrscheinlich seltener vorkommen als zuvor angenommen und daher möglicherweise irrelevant für die adoptive T-Zelltherapie sind. Diese Daten deuten darauf hin, dass die Auswahl von Zielmolekülen für die adoptive T-Zell-Therapie mit Hilfe reverser Immunologie auf der Grundlage von Bindungsalgorithmen und der Häufigkeit von Mutationen allein nicht ausreicht. Daher sind vor der Isolierung und Charakterisierung von TZRs zusätzliche Strategien wie z.B. die Analyse des MHC-Immunopeptidoms erforderlich, um die Auswahl geeigneter Zielmoleküle für die T-Zelltherapie zu verbessern. / Adoptive transfer of T cell receptor (TCR)-engineered T cells against tumour-specific neoantigens is a promising approach in cancer immunotherapy. Ideally, targeted antigens are crucial for cancer cell survival and are generated in sufficient amounts to be recognised by T cells. However, the identification of ideal targets remains challenging and requires intensive characterisation to validate sufficient antigen processing and presentation by the tumour cells. This thesis focused on the validation of HLA-A2 binding neoepitopes carrying the recurrent cancer mutations H3.3K27M, Rac1P29S, Rac2P29L or KrasG12V as targets for adoptive T cell therapy. After peptide immunisation, immune responses in a human transgenic mouse model were elicited and high-affinity TCRs successfully isolated. Although H3.3K27M-specific T cells showed high functional avidity, no recognition of cells endogenously expressing mutant H3.3 was achieved. Furthermore, a mechanism to target the common melanoma mutation Rac1P29S with a TCR raised against a heterologous mutation with higher peptide-MHC affinity was described. TCR-transduced T cells induced cytotoxicity against Rac1P29S expressing melanoma cell lines. Lastly, high-affinity TCRs specific for mutant Kras and Rac2 spliced epitopes generated by proteasome-catalysed peptide splicing were successfully isolated, however, TCR-transduced T cells did not induce an immune response against endogenously expressed mutant transgenes. The results indicate that spliced epitopes are probably less abundant than previously estimated and therefore may play a minor role in the generation of targets for adoptive T cell therapy. These data suggest that target selection using a reverse immunology approach based on binding algorithms and frequency of mutations alone is not sufficient. Thus, additional strategies to improve the selection of suitable targets such as the analysis of the MHC immunopeptidome are required prior to TCR isolation and characterisation.

Neuartige Vakzinierungsstrategien zur Aktivierung einer Tumor-spezifischen zellulären Immunantwort sind vielversprechende Ansätze zur Therapie von Tumoren, insbesondere Human Papillomvirus (HPV)-assoziierte Tumore. Bisherige HPV-Impfstudien zeigen zwar die Aktivierung einer spezifischen zellulären Immunantwort, eine Tumorreduktion bleibt jedoch aus. Um diesen Effekt auf Immunzellebene zu definieren, wurde die Wirkung der HPV-Vakzine Ad p14 im Mausmodell und an Untersuchungsmaterial humaner Tumore analysiert. In Mäusen bildeten sich HPV+ TC1-Tumore einer frühen Entwicklungsphase nach Vakzinierung zurück. Tumore einer späten Entwicklungsphase wuchsen dagegen in zwei Intervallen aus. Immunologische Eigenschaften der Tumorzellen blieben dabei unverändert. Unterschiede zeigten sich in den Frequenzen Tumor-infiltrierender Lymphozyten; in progressiven Phasen wurden nur CD4+ T Zellen nachgewiesen, in Regressionsphasen zusätzlich zytotoxische CD8+ T Zellen. Immunmodulatoren, wie Interferon alpha oder DTA-1, einem Antikörper für den Glucocorticoid-induzierten Tumornekrosefaktor-Rezeptor, unterstützten die Wirkung der Vakzine; letzterer erhöhte die Anzahl zytotoxischer CD8+ T Zellen und führte zur Abstoßung der TC1-Tumore. HPV+ Tumorgewebe des Menschen, wie auch ihre Vorstufen, zeigten im Vergleich zu anderen Tumoren, wie Bronchial oder Kolonkarzinomen einen signifikant höheren Anteil an CD4+ und CD8+ T Zellen und an Forkhead Box P3+ regulatorischen T Zellen. Die Ergebnisse deuten darauf hin, dass die immunologischen Abläufe bei der Entwicklung HPV-assoziierter Tumore mit denen vorangeschrittener chronischer Erkrankungen vergleichbar sind, in denen sich CD4+ und CD8+ T Zellantworten erschöpfen während sich gleichzeitig immunsuppressive Mechanismen verstärken. Um die Entwicklung von Impfstoffen zur Therapie HPV-assoziierter Tumore zu verbessern sollten diese Mechanismen ausführlicher betrachtet werden. / Novel vaccination strategies, activating cellular tumour specific immune responses represent a promising approach for the treatment of cancer. Especially featured for these treatments are tumours evolving from chronic human papillomavirus (HPV) infections. But current strategies have not yet proved efficacious for complete tumour regression. Addressing cellular immunological aspects of tumour vaccination, this work focused on effects of HPV vaccine Ad p14 in mice and in samples of human tumours. In mice vaccination resulted in complete regression of early stage murine HPV+ TC1 tumours. Late stage TC1 tumours increased discontinuously. During that process, TC1 cells preserved their immunological characteristics. But frequencies of tumour-infiltrating lymphocytes varied; in progressing tumours only CD4+ T cells occurred, in temporary regressing tumours also CD8+ T cells were detected. Immune modulators, like interferon alpha or glucocorticoid-induced tumour necrosis factor receptor targeting antibody DTA-1 aggravated the effects of vaccination; latter raised cytotoxic CD8+ T cell numbers and resulted in complete tumour regression. Human HPV+ tumours as well as HPV+ precancerous stages revealed numbers of CD4+ and CD8+ T cells and especially of forkhead box P3+ regulatory T cells that were significantly increased compared to melanoma, bronchial or colon carcinoma. To assist further analysis of human HPV-associated cervical cancer and facilitate studies on therapeutic approaches, a humanized mouse model was established. The present work points to immunological exhaustion in the development of HPV-related tumours comparable to chronic diseases where CD4+ and CD8+ T cells exhaust and immunosuppression by regulatory T cells increases at the same time. For the development of appropriate strategies to enhance efficacy in HPV-associated tumour therapy, further knowledge of mechanisms involved in specific T cell activation, T cell exhaustion and immunosuppression is necessary.

No / A novel series of 1,4-disubstituted aminoanthraquinones were prepared by ipso-displacement of 1,4-difluoro-5,8-dihydroxyanthraquinones by hydroxylated piperidinyl- or pyrrolidinylalkyl-amino side chains. One aminoanthraquinone (13) was further derivatized to a chloropropyl-amino analogue by treatment with triphenylphosphine-carbon tetrachloride. The compounds were evaluated in the A2780 ovarian cancer cell line and its cisplatin-resistant variants (A2780/ cp70 and A2780/MCP1). The novel anthraquinones were shown to possess up to 5-fold increased potency against the cisplatin-resistant cells compared to the wild-type cells. Growth curve analysis of the hydroxyethylaminoanthraquinone 8 in the osteosarcoma cell line U-2 OS showed that the cell cycle is not frozen, rather there is a late cell cycle arrest consistent with the action of a DNA-damaging topoisomerase II inhibitor. Accumulative apoptotic events, using time lapse photography, indicate that 8 is capable of fully engaging cell cycle arrest pathways in G2 in the absence of early apoptotic commitment. 8 and its chloropropyl analogue 13 retained significant activity against human A2780/cp70 xenografted tumors in mice.

Human cancers exhibit the common phenotype of elevated glycolytic metabolism, which causes acidification of the tissue microenvironment and may facilitate tumour invasion. In this thesis, we use mathematical models to address a series of open problems underlying the glycolytic tumour phenotype and its attendant acidity. We first explore tissue-scale consequences of metabolically-derived acid. Incorporating more biological detail into a canonical model of acidity at the tumour-host interface, we extend the range of tumour behaviours captured by the modelling framework. We then carry out an asymptotic travelling wave analysis to express invasive tumour properties in terms of fundamental parameters, and find that interstitial gaps between an advancing tumour and retreating healthy tissue, characteristic of aggressive invasion and comprising a controversial feature of the original model, are less significant under our generalised formulation. Subsequently, we evaluate a potential role of lactate---historically assumed to be a passive byproduct of glycolytic metabolism---in a perfusion-dependent metabolic symbiosis that was recently proposed as a beneficial tumour behaviour. Upon developing a minimal model of dual glucose-lactate consumption in vivo and employing a multidimensional sensitivity analysis, we find that symbiosis may not be straightforwardly beneficial for our model tumour. Moreover, new in vitro experiments, carried out by an experimental collaborator, place U87 glioblastoma tumours in a weakly symbiotic parameter regime despite their clinical malignancy. These results suggest that intratumoural metabolic cooperation is unlikely to be an important role for lactate. Finally, we examine the complex pH regulation system that governs expulsion of metabolically derived acid loads across tumour cell membranes. This system differs from the healthy system by expression of only a few key proteins, yet its dynamics are non-intuitive in the crowded and poorly perfused in vivo environment. We systematically develop a model of tumour pH regulation, beginning with a single-cell scenario and progressing to a spheroid, within a Bayesian framework that incorporates information from in vitro data contributed by a second experimental collaborator. We predict that a net effect of pH regulation is a straightforward transmembrane pH gradient, but also that existing treatments are unable to disrupt the system strongly enough to cause tumour cell death. Taken together, our models help to elucidate previously unresolved features of glycolytic tumour metabolism, and illustrate the utility of a combined mathematical, statistical, and experimental approach for testing biological hypotheses. Opportunities for further investigation are discussed.